Cytochrome 4Z1 Expression is Associated with Poor Prognosis in Colon Cancer Patients

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2012;65(2):87–108. doi:10.3322/caac.21262
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065. doi:10.1038/nrdp.2015.65
   PubMed Web of Science ®Google Scholar
• Al-Saraireh YM, Alshammari FO, Youssef AM, et al. Screening of glypican-6 expression in benign, primary and metastatic colon cancers. Clin Med Insights Oncol. 2021;15:11795549211036419. doi:10.1177/11795549211036419
   Web of Science ®Google Scholar
• Al-saraireh YM, Alshammari FOFO, Youssef AMM, et al. Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers. Sci Rep. 2021;11(1):5581. doi:10.1038/s41598-021-85188-4
   PubMed Web of Science ®Google Scholar
• Murray GI, Patimalla S, Stewart KN, Miller ID, Heys SD. Profiling the expression of cytochrome P450 in breast cancer. Histopathology. 2010;57(2):202–211. doi:10.1111/j.1365-2559.2010.03606.x
   PubMed Web of Science ®Google Scholar
• Alshammari F, Al-Saraireh YM, Youssef AMM, Al-Sarayra YM, Alrawashdeh HM. Cytochrome P450 1B1 overexpression in cervical cancers: cross-sectional study. Interact J Med Res. 2021;10(4):e31150. doi:10.2196/31150
   PubMed Web of Science ®Google Scholar
• Edson KZ, Rettie AE. CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid د‰-hydroxylase activities. Curr Top Med Chem. 2013;13(12):1429–1440. doi:10.2174/15680266113139990110
   PubMed Web of Science ®Google Scholar
• Rieger MA, Ebner R, Bell DR, et al. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res. 2004;64(7):2357–2364. doi:10.1158/0008-5472.can-03-0849
   PubMed Web of Science ®Google Scholar
• Downie D, McFadyen MC, Rooney PH, et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res. 2005;11(20):7369–7375. doi:10.1158/1078-0432.CCR-05-0466
   PubMed Web of Science ®Google Scholar
• Tradonsky A, Rubin T, Beck R, Ring B, Seitz R, Mair S. A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases. Am J Clin Pathol. 2012;137(6):918–930. doi:10.1309/AJCPF3QWIG8FWXIH
   PubMed Web of Science ®Google Scholar
• Al-saraireh Yousef M, NS Alboaisa, Mohammad AH, Omar H, Sameeh A-S, Al-Shuneigat Jehad M, Nofal mohammad N. Screening of cytochrome 4Z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues. ecancer. 2020;14:1114.
   PubMed Web of Science ®Google Scholar
• Yang X, Hutter M, Goh WWB, Bureik M. CYP4Z1 - A human cytochrome p450 enzyme that might hold the key to curing breast cancer. Curr Pharm Des. 2017;23(14):2060–2064. doi:10.2174/1381612823666170207150156
   PubMed Web of Science ®Google Scholar
• Al-saraireh YM, Alshammari FO, Youssef AM, et al. Cytochrome 4Z1 expression is associated with unfavorable survival in triple-negative breast cancers. Breast Cancer. 2021;13:565–574.
   PubMed Web of Science ®Google Scholar
• Al-saraireh YM, Alshammari FOFO, Youssef AMM, et al. Cytochrome 4Z1 expression is correlated with poor prognosis in patients with cervical cancer. Curr Oncol. 2021;28(5):3573–3584. doi:10.3390/curroncol28050306
   PubMed Web of Science ®Google Scholar
• Khayeka-Wandabwa C, Ma X, Cao X, et al. Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans. Int Immunopharmacol. 2019;73:64–71. doi:10.1016/j.intimp.2019.05.003
   PubMed Web of Science ®Google Scholar
• Yu W, Chai H, Li Y, et al. Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer. Toxicol Appl Pharmacol. 2012;264(1):73–83. doi:10.1016/j.taap.2012.07.019
   PubMed Web of Science ®Google Scholar
• Savas U, Hsu MH, Griffin KJ, Bell DR, Johnson EF. Conditional regulation of the human CYP4X1 and CYP4Z1 genes. Arch Biochem Biophys. 2005;436(2):377–385. doi:10.1016/j.abb.2005.02.022
   PubMed Web of Science ®Google Scholar
• Zollner A, Dragan CA, Pistorius D, et al. Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid. Biol Chem. 2009;390(4):313–317. doi:10.1515/BC.2009.030
   PubMed Web of Science ®Google Scholar
• McDonald MG, Ray S, Amorosi CJ, et al. Expression and functional characterization of breast cancer-associated cytochrome P450 4Z1 in saccharomyces cerevisiae. Drug Metab Dispos. 2019;45(12):1364–1371. doi:10.1124/dmd.117.078188
   Web of Science ®Google Scholar
• Du W, Machalz D, Yan Q, Sorensen EJ, Wolber G, Bureik M. Importance of asparagine-381 and arginine-487 for substrate recognition in CYP4Z1. Biochem Pharmacol. 2020;174:113850. doi:10.1016/j.bcp.2020.113850
   PubMed Web of Science ®Google Scholar
• Yan Q, Machalz D, Zأllner A, Sorensen EJ, Wolber G, Bureik M. Efficient substrate screening and inhibitor testing of human CYP4Z1 using permeabilized recombinant fission yeast. Biochem Pharmacol. 2017;15(146):174–187. doi:10.1016/j.bcp.2017.09.011
   Google Scholar
• Kowalski JP, McDonald MG, Pelletier RD, Hanenberg H, Wiek C, Rettie AE. Design and characterization of the first selective and potent mechanism-based inhibitor of cytochrome P450 4Z1. J Med Chem. 2020;63(9):4824–4836. doi:10.1021/acs.jmedchem.0c00101
   PubMed Web of Science ®Google Scholar
• Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol. 2012;3(3):153–173. doi:10.3978/j.issn.2078-6891.2012.030
   PubMedGoogle Scholar
• Alnabulsi A, Swan R, Cash B, Murray GI. The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance. Br J Cancer. 2017;116(12):1612–1620. doi:10.1038/bjc.2017.135
   PubMed Web of Science ®Google Scholar
• Kumarakulasingham M, Rooney PH, Dundas SR, et al. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res. 2005;11(10):3758–3765. doi:10.1158/1078-0432.CCR-04-1848
   PubMed Web of Science ®Google Scholar
• Murray GI, Patimalla S, Stewart KN, Miller ID, Heys SD. Profiling the expression of cytochrome P450 in breast cancer. Histopathology. 2009;57(2):202–211. doi:10.1111/j.1365-2559.2010.03606.x
   Web of Science ®Google Scholar
• Nunna V, Jalal N, Bureik M. Anti-CYP4Z1 autoantibodies detected in breast cancer patients. Cell Mol Immunol. 2017;14(6):572–574. doi:10.1038/cmi.2017.21
   PubMed Web of Science ®Google Scholar
• Zheng L, Guo Q, Xiang C, et al. Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells. J Hematol Oncol. 2019;12(1):23. doi:10.1186/s13045-019-0697-6
   PubMed Web of Science ®Google Scholar
• McDonald MG, Ray S, Amorosi CJ, et al. Expression and functional characterization of breast cancer-associated cytochrome P450 4Z1 in Saccharomyces cerevisiae. Drug Metab Dispos. 2017;45(12):1364–1371. doi:10.1124/dmd.117.078188
   PubMed Web of Science ®Google Scholar